Insider Trading February 24, 2026

RENN Fund President Murray Stahl Buys 1,134 Shares Worth $3,254

Stahl increases direct and indirect holdings in RENN Fund as shares trade near their 52-week high

By Avery Klein RCG
RENN Fund President Murray Stahl Buys 1,134 Shares Worth $3,254
RCG

Murray Stahl, President and Co-Portfolio Manager of RENN Fund, Inc. (RCG), purchased a total of 1,134 common shares on February 23, 2026, paying $2.87 per share for an aggregate outlay of $3,254. The transaction included both direct and indirect acquisitions through several affiliated entities. After the purchases, Stahl directly holds 149,894 shares. Market data referenced in the filing show RCG trading at $2.90 and delivering an 11% year-to-date return, while InvestingPro figures note a trailing P/E of 5.54 and positive earnings over the last twelve months.

Key Points

  • Murray Stahl purchased 1,134 shares of RENN Fund on February 23, 2026, at $2.87 per share, totaling $3,254.
  • The purchases consisted of 360 shares bought directly by Stahl and 774 shares acquired indirectly through affiliated entities and his spouse.
  • After the transactions, Stahl directly owns 149,894 shares; RCG is trading at $2.90 and is reported to be 11% higher year-to-date with a trailing P/E of 5.54 and profitability over the last twelve months.

Murray Stahl, who serves as President and Co-Portfolio Manager of RENN Fund, Inc. (EXCHANGE: RCG), recorded insider purchases of the fund's common stock on February 23, 2026. The filing shows a total of 1,134 shares were acquired at a per-share price of $2.87, producing a combined purchase amount of $3,254.

The reporting breaks the transaction down between direct and indirect purchases. Stahl's direct acquisition accounted for 360 shares. Indirect purchases associated with him were carried out through a number of entities: 18 shares via his spouse, 180 shares through Fromex Equity Corp., another 180 shares via FRMO Corp., 296 shares through Horizon Common Inc., 18 shares via Horizon Kinetics Hard Assets LLC, and 82 shares through Horizon Kinetics Asset Management LLC.

Following the February 23 trades, Stahl's direct ownership in RENN Fund stands at 149,894 shares. The filing also notes he holds additional indirect positions through the listed entities, while disclaiming beneficial ownership except to the extent of his pecuniary interest.

Market context included in the disclosure shows RCG trading at $2.90, a level described as near the stock's 52-week high of $2.88. The filing reports that shares have produced an 11% return year-to-date. Supplemental data from InvestingPro highlighted in the report indicates RCG carries a price-to-earnings ratio of 5.54 and remained profitable over the last twelve months. The InvestingPro platform is also noted as offering three additional "ProTips" for investors seeking further insight into RCG.

The filing provides a clear ledger of who acquired the indirect holdings and the number of shares attributed to each affiliated party, while Stahl's disclaimer of beneficial ownership is included verbatim in the disclosure. No additional commentary or forward-looking statements are included in the regulatory filing.


Contextual note - The transaction is factual and limited to the data disclosed in the insider filing. The report does not include further analysis or commentary beyond the numbers and statements provided in that filing and the brief InvestingPro metrics referenced.

Risks

  • The filing states Stahl disclaims beneficial ownership of the indirectly held shares except to the extent of his pecuniary interest - the degree of control or benefit is therefore not fully specified, creating ambiguity for investors.
  • RCG is trading near its reported 52-week high of $2.88; prices at or near highs can be associated with short-term volatility for equity investors.
  • While InvestingPro notes a trailing P/E of 5.54 and profitability over the past twelve months, those metrics are historical and do not guarantee future financial performance.

More from Insider Trading

NeonC/NeOnc President Buys $153,398 in Stock as Company Advances Financing and Clinical Timeline Apr 6, 2026 Edwards Lifesciences Executive Executes Option Exercise, Sells 1,019 Shares Apr 6, 2026 Penumbra Director Executes $32,822 Stock Sale Amid Deal and Upbeat Quarterly Results Apr 6, 2026 Power Integrations VP Sells 313 Shares to Cover Tax Bill; Stock Up 45% YTD Apr 6, 2026 Lipocine Director Purchases 123,000 Shares Amid Mixed Clinical News Apr 6, 2026